

# Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders

Brian J. O’Roak,<sup>1</sup> Laura Vives,<sup>1</sup> Wenqing Fu,<sup>1</sup> Jarrett D. Egertson,<sup>1</sup> Ian B. Stanaway,<sup>1</sup> Ian G. Phelps,<sup>2,3</sup> Gemma Carvill,<sup>2,3</sup> Akash Kumar,<sup>1</sup> Choli Lee,<sup>1</sup> Katy Ankenman,<sup>4</sup> Jeff Munson,<sup>4</sup> Joseph B. Hiatt,<sup>1</sup> Emily H. Turner,<sup>1</sup> Roie Levy,<sup>1</sup> Diana R. O’Day,<sup>2</sup> Niklas Krumm,<sup>1</sup> Bradley P. Coe,<sup>1</sup> Beth K. Martin,<sup>1</sup> Elhanan Borenstein,<sup>1,5,6</sup> Deborah A. Nickerson,<sup>1</sup> Heather C. Mefford,<sup>2,3</sup> Dan Doherty,<sup>2,3</sup> Joshua M. Akey,<sup>1</sup> Raphael Bernier,<sup>4</sup> Evan E. Eichler,<sup>1,7\*</sup> Jay Shendure<sup>1\*</sup>

<sup>1</sup>Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA.

<sup>2</sup>Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98195, USA. <sup>3</sup>Seattle Children’s Hospital, Seattle, WA 98105, USA. <sup>4</sup>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195, USA. <sup>5</sup>Department of Computer Science and Engineering, University of Washington, Seattle, WA 98195, USA. <sup>6</sup>Santa Fe Institute, Santa Fe, NM 87501, USA.

<sup>7</sup>Howard Hughes Medical Institute, Seattle, WA 98195, USA.

\*To whom correspondence should be addressed. E-mail: shendure@uw.edu (J.S.) and eee@gs.washington.edu (E.E.E.)

**Exome sequencing studies of autism spectrum disorders (ASD) have identified many de novo mutations, but few recurrently disrupted genes. We therefore developed a modified molecular inversion probe method enabling ultra-low-cost candidate gene resequencing in very large cohorts. To demonstrate the power of this approach, we captured and sequenced 44 candidate genes in 2,446 ASD probands. We discovered 27 de novo events in 16 genes, 59% of which are predicted to truncate proteins or disrupt splicing. We estimate that recurrent disruptive mutations in six genes—*CHD8*, *DYRK1A*, *GRIN2B*, *TBR1*, *PTEN*, and *TBL1XR1*—may contribute to 1% of sporadic ASD. Our data support associations between specific genes and reciprocal subphenotypes (*CHD8*-macrocephaly, *DYRK1A*-microcephaly) and replicate the importance of a  $\beta$ -catenin/chromatin remodeling network to ASD etiology.**

There is considerable interest in the contribution of rare variants and de novo mutations to the genetic basis of complex phenotypes such as autism spectrum disorders (ASD). However, because of extreme genetic heterogeneity, the sample sizes required to implicate any single gene in a complex phenotype are extremely large (1). Exome sequencing has identified hundreds of ASD candidate genes on the basis of de novo mutations observed in the affected offspring of unaffected parents (2–6). Yet, only a single mutation was observed in nearly all such genes, and sequencing of over 900 trios was insufficient to establish mutations at any single gene as definitive genetic risk factors (2–6).

To address this, we sought to evaluate candidate genes identified by exome sequencing (2, 3) for de novo mutations in a much larger ASD cohort. We developed a modified molecular inversion probe (MIP) strategy (Fig. 1A) (7–9) with novel algorithms for MIP design; an optimized, automatable workflow with robust performance and minimal DNA input; extensive multiplexing of samples while sequencing; and reagent costs of less than \$1 per gene per sample. Extensive validation using several probe sets and sample collections demonstrated 99% sensitivity and 98% positive predictive value for single nucleotide variants at well-covered positions i.e., 92% to 98% of targeted bases (figs. S1–S7 and tables S1–S9) (10).

We applied this method to 2,494 ASD probands from the Simons Simplex Collection (SSC) (11) using two probe sets [ASD1 (6 genes) and ASD2 (38 genes)] to target 44 ASD candidate genes (12). Preliminary results using ASD1 on a subset of the SSC implicated *GRIN2B* as a

risk locus (3). The 44 genes were selected from 192 candidates (2, 3), focusing on genes with disruptive mutations, associations with syndromic autism (13), overlap with known or suspected neurodevelopmental CNV risk loci (13, 14), structural similarities, and/or neuronal expression (table S3). Although a few of the 44 genes have been reported disrupted in individuals with neurodevelopmental or neuropsychiatric disorders (often including concurrent dysmorphologies), their role in so-called idiopathic ASD has not been rigorously established. Twenty-three of the 44 genes intersect a 49-member  $\beta$ -catenin/chromatin remodeling protein-protein interaction (PPI) network (2) or an expanded 74-member network (figs. S8 and S9) (3, 4).

We required samples to successfully capture with both probe sets, yielding 2,446 ASD probands with MIP data, 2,364 of which had only MIP data and 82 of which we previously exome sequenced (2, 3). The high GC content of several candidates required considerable rebalancing to improve capture uniformity (12) (figs. S3A and S10). Nevertheless, the reproducible behavior of most MIPs allowed us to identify copy number variation at targeted genes, including several inherited duplications (figs. S11 and S12 and table S10).

To discover de novo mutations, we first identified candidate sites by filtering against variants observed in other cohorts, including non-ASD exomes and MIP-based resequencing of 762 healthy, non-ASD individuals (12). The remaining candidates were further tested by MIP-based resequencing of the proband’s parents and, if potentially de novo, confirmed by Sanger sequencing of the parent-child trio (10, 12). We discovered 27 de novo mutations that occurred in 16 of the 44 genes (Fig. 1, B–E; Table 1; and table S11). Consistent with an increased sensitivity for MIP-based resequencing, six of these were not reported in exome-sequenced individuals (Table 1, tables S5 and S11, and fig. S13) (3, 4, 6). Notably, the proportion of de novo events that are severely disruptive, i.e., coding indels, nonsense mutations, and splice-site disruptions (17/27 or 0.63), is fourfold greater than the expected proportion for random de novo mutations (0.16, binomial  $p = 4.9 \times 10^{-8}$ ) (table S12) (15).

Given their extremely low frequency, accurately establishing expectation for de novo mutations in a locus-specific manner through the sequencing of control trios is impractical. We therefore developed a probabilistic model that incorporates the overall rate of mutation in coding sequences, estimates of relative locus-specific rates based on human-chimpanzee fixed differences (fig. S14 and table S13), and other factors that may influence the distribution of mutation classes, e.g., codon structure (12). We applied this model to estimate (by simulation) the probability of observing additional de novo mutations during MIP-based resequencing of the SSC cohort. To compare expectation and observation, we treated missense mutations as one class and severe disruptions as a second class. Thus, we could evaluate the probability at a given

locus of observing at least X de novo mutations, of which at least Y belong to the severe class.

We found evidence of mutation burden—a higher rate of de novo mutation than expected—in the overall set of 44 genes (observed  $n = 27$  vs. mean expected  $n = 5.6$ , simulated  $p < 2 \times 10^{-9}$ ) (Fig. 2A). The burden was driven by the severe class (observed  $n = 17$  vs. mean expected  $n = 0.58$ , simulated  $p < 2 \times 10^{-9}$ ). Most severe class mutations intersected the 74-member PPI network (16/17), although only 23/44 genes are in this network (binomial  $p = 0.0002$ ) (12). Furthermore, 21/27 mutations occurred in network-associated genes (binomial  $p = 0.004$ ). Of the six individual genes (*CHD8*, *GRIN2B*, *DYRK1A*, *PTEN*, *TBR1*, and *TBL1XR1*) with evidence of mutation burden (alpha of 0.05 after a Holm-Bonferroni correction for multiple testing (Fig. 2A); *TBL1XR1* is not significant with a more conservative Bonferroni correction), five fall within the  $\beta$ -catenin/chromatin remodeling network. In our combined MIP and exome data, ~1% (24/2,573) of ASD probands harbor a de novo mutation in one of these six genes, with *CHD8* representing 0.35% (9/2,573) (Fig. 1B and Table 1).

For these analyses, we conservatively used the highest available empirical estimate of the overall mutation rate in coding sequences (3). With the exception of *TBL1XR1*, these results were robust to doubling the overall mutation rate, or to using the upper bound of the 95% confidence interval of the locus-specific rate estimate for each of these genes (10). Moreover, we obtained similar results regardless of whether parameters were estimated from rare, segregating variation or from de novo mutations in unaffected siblings (10), as well as with a sequence composition model based on genome-wide de novo mutation (16). Exome sequencing of non-ASD individuals (unaffected siblings or non-ASD cohorts) further supports these conclusions (table S14) (10).

We also validated 23 inherited, severely disruptive variants in the 44 genes (table S15). Two probands with such variants carry de novo 16p11.2 duplications (table S16). Combining de novo and inherited events, severe class variants were observed at twice the rate in MIP-sequenced probands as compared with MIP-sequenced healthy, non-ASD individuals (Fisher's exact test,  $p = 0.083$ ). Severe class variants were not transmitted to 14/20 unaffected siblings (binomial  $p = 0.058$ ) (table S15). However, larger cohorts than currently exist will be needed to fully evaluate these modest trends.

We analyzed phenotypic data on probands with mutations in the six implicated genes. Each was diagnosed with autism on the basis of current, strict, gold-standard criteria. No obvious dysmorphologies or recurrent comorbidities were present. Probands tended to fall into the intellectual disability range for nonverbal IQ (NVIQ) (mean 58.3) (Table 1). However, for *CHD8*, probands were found to have NVIQ scores ranging from profoundly impaired to average (mean 62.2, range 19-98).

Given the previously observed microcephaly in our index *DYRK1A* mutation case, macrocephaly in both probands with *CHD8* mutations (3), and the association of these traits with other syndromic loci (13, 17), we reexamined head circumference (HC) in the larger set of probands with protein-truncation or splice-site de novo events using age and sex normalized HC Z-scores (12) (Fig. 2B). For *CHD8* ( $n = 8$ ), we observed significantly larger head sizes relative to individuals screened without *CHD8* mutations (two-sample permutation test, two-sided  $p = 0.0007$ ). De novo *CHD8* mutations are present in ~2% of macrocephalic ( $HC > 2.0$ ) SSC probands ( $n = 366$ ), suggesting a useful phenotype for patient subclassification. For *DYRK1A* ( $n = 3$ ), we observed significantly smaller head sizes relative to individuals screened without *DYRK1A* mutations (two-sample permutation test, two-sided  $p = 0.0005$ ). Comparison of head size in the context of the families (Fig. 2, C and D, and table S17) provides further support for this reciprocal trend (10). These findings are also consistent with case reports of patients with structural rearrangements and mouse transgenic models that implicate *DYRK1A* and *CHD8* as regulators of brain growth (18–21). Macrocephaly was also observed

in individuals with de novo and inherited *PTEN* mutations (22).

Our data support an important role for de novo mutations in six genes in ~1% of sporadic ASD. As the SSC was specifically established for simplex ASD and as its probands generally have higher cognitive functioning than has been reported in other ASD cohorts (11), it is unknown how our findings will translate into other cohorts. Furthermore, while implicating specific loci in ASD, our data are insufficient to evaluate whether the observed de novo mutations are sufficient to cause ASD (tables S16 and S18).

Exome sequencing and CNV studies suggest that there are hundreds of relevant genetic loci for ASD. Technologies and study designs directed at identifying de novo mutations, both for the discovery of ASD candidate genes as well as for their validation, provide sufficient power to implicate individual genes from a relatively small number of events. The analytical framework described here can be applied to any other disorder—simple or complex—for which de novo coding mutations are suspected to contribute to risk. Additionally, the experimental methods presented here are broadly useful for the rapid and economical resequencing of candidate genes in extremely large cohorts, as may be required for the definitive implication of rare variants or de novo mutations in any genetically complex disorder.

#### References and Notes

1. G. V. Kryukov, A. Shpunt, J. A. Stamatoyannopoulos, S. R. Sunyaev, Power of deep, all-exon resequencing for discovery of human trait genes. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 3871 (2009). doi:10.1073/pnas.0812824106 Medline
2. B. J. O'Roak *et al.*, Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. *Nat. Genet.* **43**, 585 (2011). doi:10.1038/ng.835 Medline
3. B. J. O'Roak *et al.*, Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature* **485**, 246 (2012). doi:10.1038/nature10989 Medline
4. S. J. Sanders *et al.*, De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature* **485**, 237 (2012). doi:10.1038/nature10945 Medline
5. B. M. Neale *et al.*, Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* **485**, 242 (2012). doi:10.1038/nature11011 Medline
6. I. Iossifov *et al.*, De novo gene disruptions in children on the autistic spectrum. *Neuron* **74**, 285 (2012). doi:10.1016/j.neuron.2012.04.009 Medline
7. E. H. Turner, C. Lee, S. B. Ng, D. A. Nickerson, J. Shendure, Massively parallel exon capture and library-free resequencing across 16 genomes. *Nat. Methods* **6**, 315 (2009). doi:10.1038/nmeth.f.248 Medline
8. G. J. Porreca *et al.*, Multiplex amplification of large sets of human exons. *Nat. Methods* **4**, 931 (2007). doi:10.1038/nmeth1110 Medline
9. S. Krishnakumar *et al.*, A comprehensive assay for targeted multiplex amplification of human DNA sequences. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 9296 (2008). doi:10.1073/pnas.0803240105 Medline
10. See supplementary text on Science Online.
11. G. D. Fischbach, C. Lord, The Simons Simplex Collection: A resource for identification of autism genetic risk factors. *Neuron* **68**, 192 (2010). doi:10.1016/j.neuron.2010.10.006 Medline
12. Materials and methods are available as supplementary material on Science Online.
13. C. Betancur, Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting. *Brain Res.* **1380**, 42 (2011). doi:10.1016/j.brainres.2010.11.078 Medline
14. G. M. Cooper *et al.*, A copy number variation morbidity map of developmental delay. *Nat. Genet.* **43**, 838 (2011). doi:10.1038/ng.909 Medline
15. M. Lynch, Rate, molecular spectrum, and consequences of human mutation. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 961 (2010). doi:10.1073/pnas.0912629107 Medline
16. A. Kong *et al.*, Rate of de novo mutations and the importance of father's age to disease risk. *Nature* **488**, 471 (2012). doi:10.1038/nature11396 Medline
17. C. A. Williams, A. Dagli, A. Battaglia, Genetic disorders associated with macrocephaly. *Am. J. Med. Genet. A.* **146A**, 2023

- (2008). [doi:10.1002/ajmg.a.32434](https://doi.org/10.1002/ajmg.a.32434) [Medline](#)
18. R. S. Møller *et al.*, Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. *Am. J. Hum. Genet.* **82**, 1165 (2008). [doi:10.1016/j.ajhg.2008.03.001](https://doi.org/10.1016/j.ajhg.2008.03.001) [Medline](#)
  19. B. W. van Bon *et al.*, Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. *Clin. Genet.* **79**, 296 (2011). [doi:10.1111/j.1399-0004.2010.01544.x](https://doi.org/10.1111/j.1399-0004.2010.01544.x) [Medline](#)
  20. F. Guedj *et al.*, DYRK1A: A master regulatory protein controlling brain growth. *Neurobiol. Dis.* **46**, 190 (2012). [doi:10.1016/j.nbd.2012.01.007](https://doi.org/10.1016/j.nbd.2012.01.007) [Medline](#)
  21. M. E. Talkowski *et al.*, Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell* **149**, 525 (2012). [doi:10.1016/j.cell.2012.03.028](https://doi.org/10.1016/j.cell.2012.03.028) [Medline](#)
  22. J. Zhou, L. F. Parada, PTEN signaling in autism spectrum disorders. *Curr. Opin. Neurobiol.* **22**, 873 (2012). [doi:10.1016/j.conb.2012.05.004](https://doi.org/10.1016/j.conb.2012.05.004) [Medline](#)
  23. I. Letunic, T. Doerks, P. Bork, SMART 7: Recent updates to the protein domain annotation resource. *Nucleic Acids Res.* **40**(Database issue), D302 (2012). [doi:10.1093/nar/gkr931](https://doi.org/10.1093/nar/gkr931) [Medline](#)
  24. N. Sugimoto, S. Nakano, M. Yoneyama, K. Honda, Improved thermodynamic parameters and helix initiation factor to predict stability of DNA duplexes. *Nucleic Acids Res.* **24**, 4501 (1996). [doi:10.1093/nar/24.22.4501](https://doi.org/10.1093/nar/24.22.4501) [Medline](#)
  25. Y. Wang *et al.*, Analysis of molecular inversion probe performance for allele copy number determination. *Genome Biol.* **8**, R246 (2007). [doi:10.1186/gb-2007-8-11-r246](https://doi.org/10.1186/gb-2007-8-11-r246) [Medline](#)
  26. N. Krumm *et al.*, NHLBI Exome Sequencing Project, Copy number variation detection and genotyping from exome sequence data. *Genome Res.* **22**, 1525 (2012). [doi:10.1101/gr.138115.112](https://doi.org/10.1101/gr.138115.112) [Medline](#)
  27. J. Ren *et al.*, DOG 1.0: Illustrator of protein domain structures. *Cell Res.* **19**, 271 (2009). [doi:10.1038/cr.2009.6](https://doi.org/10.1038/cr.2009.6) [Medline](#)
  28. W.-H. Li, Molecular Evolution. (Sinauer Associates, Sunderland, MA, 1997).
  29. J. A. Tennesen *et al.*, Broad GO; Seattle GO; NHLBI Exome Sequencing Project, Evolution and functional impact of rare coding variation from deep sequencing of human exomes. *Science* **337**, 64 (2012). [doi:10.1126/science.1219240](https://doi.org/10.1126/science.1219240) [Medline](#)
  30. J. Q. Chen *et al.*, Variation in the ratio of nucleotide substitution and indel rates across genomes in mammals and bacteria. *Mol. Biol. Evol.* **26**, 1523 (2009). [doi:10.1093/molbev/msp063](https://doi.org/10.1093/molbev/msp063) [Medline](#)
  31. A. F. Roche, D. Mukherjee, S. M. Guo, W. M. Moore, Head circumference reference data: Birth to 18 years. *Pediatrics* **79**, 706 (1987). [Medline](#)
  32. T. Hothorn, K. Hornik, M. A. V. van de Wiel, A. Zeileis, Implementing a class of permutation tests: The coin package. *J. Stat. Softw.* **28**, 1 (2008).
  33. J. Deng *et al.*, Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. *Nat. Biotechnol.* **27**, 353 (2009). [doi:10.1038/nbt.1530](https://doi.org/10.1038/nbt.1530) [Medline](#)
  34. A. Amiri *et al.*, Pten deletion in adult hippocampal neural stem/progenitor cells causes cellular abnormalities and alters neurogenesis. *J. Neurosci.* **32**, 5880 (2012). [doi:10.1523/JNEUROSCI.5462-11.2012](https://doi.org/10.1523/JNEUROSCI.5462-11.2012) [Medline](#)
  35. M. Nishiyama, A. I. Skultchi, K. I. Nakayama, Histone H1 recruitment by CHD8 is essential for suppression of the Wnt- $\beta$ -catenin signaling pathway. *Mol. Cell. Biol.* **32**, 501 (2012). [doi:10.1128/MCB.06409-11](https://doi.org/10.1128/MCB.06409-11) [Medline](#)
  36. M. Nishiyama *et al.*, CHD8 suppresses p53-mediated apoptosis through histone H1 recruitment during early embryogenesis. *Nat. Cell Biol.* **11**, 172 (2009). [doi:10.1038/ncb1831](https://doi.org/10.1038/ncb1831) [Medline](#)
  37. B. A. Thompson, V. Tremblay, G. Lin, D. A. Bochar, CHD8 is an ATP-dependent chromatin remodeling factor that regulates beta-catenin target genes. *Mol. Cell. Biol.* **28**, 3894 (2008). [doi:10.1128/MCB.00322-08](https://doi.org/10.1128/MCB.00322-08) [Medline](#)
  38. F. Zahir *et al.*, Novel deletions of 14q11.2 associated with developmental delay, cognitive impairment and similar minor anomalies in three children. *J. Med. Genet.* **44**, 556 (2007). [doi:10.1136/jmg.2007.050823](https://doi.org/10.1136/jmg.2007.050823) [Medline](#)
  39. F. Bedogni *et al.*, Tbr1 regulates regional and laminar identity of postmitotic neurons in developing neocortex. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 13129 (2010). [doi:10.1073/pnas.1002285107](https://doi.org/10.1073/pnas.1002285107) [Medline](#)
  40. S. Endeley *et al.*, Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat. Genet.* **42**, 1021 (2010). [doi:10.1038/ng.677](https://doi.org/10.1038/ng.677) [Medline](#)
  41. R. A. Myers *et al.*, A population genetic approach to mapping neurological disorder genes using deep resequencing. *PLoS Genet.* **7**, e1001318 (2011). [doi:10.1371/journal.pgen.1001318](https://doi.org/10.1371/journal.pgen.1001318) [Medline](#)
  42. V. Fotaki *et al.*, Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. *Mol. Cell. Biol.* **22**, 6636 (2002). [doi:10.1128/MCB.22.18.6636-6647.2002](https://doi.org/10.1128/MCB.22.18.6636-6647.2002) [Medline](#)
  43. R. E. Green *et al.*, A draft sequence of the Neandertal genome. *Science* **328**, 710 (2010). [doi:10.1126/science.1188021](https://doi.org/10.1126/science.1188021) [Medline](#)
  44. J. Y. Hong *et al.*, Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway. *J. Cell Sci.* **125**, 561 (2012). [doi:10.1242/jcs.086173](https://doi.org/10.1242/jcs.086173) [Medline](#)
  45. J. Li, C. Y. Wang, TBL1-TBLR1 and beta-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. *Nat. Cell Biol.* **10**, 160 (2008). [doi:10.1038/ncb1684](https://doi.org/10.1038/ncb1684) [Medline](#)
  46. H. K. Choi *et al.*, Reversible SUMOylation of TBL1-TBLR1 regulates  $\beta$ -catenin-mediated Wnt signaling. *Mol. Cell* **43**, 203 (2011). [doi:10.1016/j.molcel.2011.05.027](https://doi.org/10.1016/j.molcel.2011.05.027) [Medline](#)
  47. S. J. Sanders *et al.*, Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron* **70**, 863 (2011). [doi:10.1016/j.neuron.2011.05.002](https://doi.org/10.1016/j.neuron.2011.05.002) [Medline](#)
  48. D. Horn *et al.*, Identification of FOXP1 deletions in three unrelated patients with mental retardation and significant speech and language deficits. *Hum. Mutat.* **31**, E1851 (2010). [doi:10.1002/humu.21362](https://doi.org/10.1002/humu.21362) [Medline](#)
  49. F. F. Hamdan *et al.*, De novo mutations in FOXP1 in cases with intellectual disability, autism, and language impairment. *Am. J. Hum. Genet.* **87**, 671 (2010). [doi:10.1016/j.ajhg.2010.09.017](https://doi.org/10.1016/j.ajhg.2010.09.017) [Medline](#)
  50. L. Feuk *et al.*, Absence of a paternally inherited FOXP2 gene in developmental verbal dyspraxia. *Am. J. Hum. Genet.* **79**, 965 (2006). [doi:10.1086/508902](https://doi.org/10.1086/508902) [Medline](#)
  51. C. S. Lai *et al.*, The SPCH1 region on human 7q31: Genomic characterization of the critical interval and localization of translocations associated with speech and language disorder. *Am. J. Hum. Genet.* **67**, 357 (2000). [doi:10.1086/303011](https://doi.org/10.1086/303011) [Medline](#)
  52. X. Wei *et al.*, NISC Comparative Sequencing Program, Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat. Genet.* **43**, 442 (2011). [doi:10.1038/ng.810](https://doi.org/10.1038/ng.810) [Medline](#)
  53. P. Awadalla *et al.*, Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. *Am. J. Hum. Genet.* **87**, 316 (2010). [doi:10.1016/j.ajhg.2010.07.019](https://doi.org/10.1016/j.ajhg.2010.07.019) [Medline](#)
  54. P. Jia *et al.*, International Schizophrenia Consortium, Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. *PLoS Comput. Biol.* **8**, e1002587 (2012). [doi:10.1371/journal.pcbi.1002587](https://doi.org/10.1371/journal.pcbi.1002587) [Medline](#)
  55. J. Tarabeux *et al.*, S2D team, Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. *Transl. Psychiatry* **1**, e55 (2011). [doi:10.1038/tp.2011.52](https://doi.org/10.1038/tp.2011.52) [Medline](#)
  56. T. Barak *et al.*, Recessive LAMC3 mutations cause malformations of occipital cortical development. *Nat. Genet.* **43**, 590 (2011). [doi:10.1038/ng.836](https://doi.org/10.1038/ng.836) [Medline](#)
  57. C. Lossin, A catalog of SCN1A variants. *Brain Dev.* **31**, 114 (2009). [doi:10.1016/j.braindev.2008.07.011](https://doi.org/10.1016/j.braindev.2008.07.011) [Medline](#)
  58. K. S. Kim *et al.*, Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 3908 (2006). [doi:10.1073/pnas.0508812103](https://doi.org/10.1073/pnas.0508812103) [Medline](#)
  59. A. Pinhasov *et al.*, Activity-dependent neuroprotective protein: A novel gene essential for brain formation. *Brain Res. Dev. Brain Res.* **144**, 83 (2003). [doi:10.1016/S0165-3806\(03\)00162-7](https://doi.org/10.1016/S0165-3806(03)00162-7) [Medline](#)
  60. J. M. Hill *et al.*, Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. *J. Mol. Neurosci.* **31**, 183 (2007). [Medline](#)
  61. M. J. Wat *et al.*, Recurrent microdeletions of 15q25.2 are associated with increased risk of congenital diaphragmatic hernia, cognitive deficits and possibly Diamond-Blackfan anaemia. *J. Med. Genet.* **47**, 777 (2010). [doi:10.1136/jmg.2009.075903](https://doi.org/10.1136/jmg.2009.075903) [Medline](#)
  62. G. W. Santen *et al.*, Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat. Genet.* **44**, 379 (2012). [doi:10.1038/ng.2217](https://doi.org/10.1038/ng.2217) [Medline](#)
  63. J. Hoyer *et al.*, Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. *Am. J. Hum. Genet.* **90**, 565 (2012). [doi:10.1016/j.ajhg.2012.02.007](https://doi.org/10.1016/j.ajhg.2012.02.007) [Medline](#)
  64. C. Halgren *et al.*, Corpus callosum abnormalities, intellectual disability, speech impairment, and autism in patients with haploinsufficiency of ARID1B. *Clin. Genet.* **82**, 248 (2012). [doi:10.1111/j.1399-0004.2011.01755.x](https://doi.org/10.1111/j.1399-0004.2011.01755.x)



- [Medline](#)
65. A. S. Nord *et al.*; STAART Psychopharmacology Network, Reduced transcript expression of genes affected by inherited and de novo CNVs in autism. *Eur. J. Hum. Genet.* **19**, 727 (2011). [doi:10.1038/ejhg.2011.24](#) [Medline](#)
  66. M. Kishi, Y. A. Pan, J. G. Crump, J. R. Sanes, Mammalian SAD kinases are required for neuronal polarization. *Science* **307**, 929 (2005). [doi:10.1126/science.1107403](#) [Medline](#)
  67. T. Batsukh *et al.*, CHD8 interacts with CHD7, a protein which is mutated in CHARGE syndrome. *Hum. Mol. Genet.* **19**, 2858 (2010). [doi:10.1093/hmg/ddq189](#) [Medline](#)
  68. M. C. Jongmans *et al.*, CHARGE syndrome: The phenotypic spectrum of mutations in the CHD7 gene. *J. Med. Genet.* **43**, 306 (2006). [doi:10.1136/jmg.2005.036061](#) [Medline](#)
  69. L. Feng, N. S. Allen, S. Simo, J. A. Cooper, Cullin 5 regulates Dab1 protein levels and neuron positioning during cortical development. *Genes Dev.* **21**, 2717 (2007). [doi:10.1101/gad.1604207](#) [Medline](#)
  70. D. Levy *et al.*, Rare de novo and transmitted copy-number variation in autistic spectrum disorders. *Neuron* **70**, 886 (2011). [doi:10.1016/j.neuron.2011.05.015](#) [Medline](#)
  71. H. M. El-Tahir *et al.*, Expression of hepatoma-derived growth factor family members in the adult central nervous system. *BMC Neurosci.* **7**, 6 (2006). [doi:10.1186/1471-2202-7-6](#) [Medline](#)
  72. B. Felder *et al.*, FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome. *Am. J. Med. Genet. A.* **149A**, 952 (2009). [doi:10.1002/ajmg.a.32779](#) [Medline](#)
  73. M. E. Talkowski *et al.*, Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder. *Am. J. Hum. Genet.* **89**, 551 (2011). [doi:10.1016/j.ajhg.2011.09.011](#) [Medline](#)
  74. S. R. Williams *et al.*, Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures. *Eur. J. Hum. Genet.* **18**, 436 (2010). [doi:10.1038/ejhg.2009.199](#) [Medline](#)
  75. A. Millson *et al.*, Chromosomal loss of 3q26.3-3q26.32, involving a partial neuroligin 1 deletion, identified by genomic microarray in a child with microcephaly, seizure disorder, and severe intellectual disability. *Am. J. Med. Genet. A.* (2011). [10.1002/ajmg.a.34349](#) [Medline](#)
  76. J. T. Glessner *et al.*, Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. *Nature* **459**, 569 (2009). [doi:10.1038/nature07953](#) [Medline](#)
  77. N. Van der Aa, G. Vandeweyer, R. F. Kooy, A boy with mental retardation, obesity and hypertrichosis caused by a microdeletion of 19p13.12. *Eur. J. Med. Genet.* **53**, 291 (2010). [doi:10.1016/j.ejmg.2010.05.006](#) [Medline](#)
  78. Y. H. Chen, M. T. Tsai, C. K. Shaw, C. H. Chen, Mutation analysis of the human NR4A2 gene, an essential gene for midbrain dopaminergic neurogenesis, in schizophrenic patients. *Am. J. Med. Genet.* **105**, 753 (2001). [doi:10.1002/ajmg.10036](#) [Medline](#)
  79. W. D. Le *et al.*, Mutations in NR4A2 associated with familial Parkinson disease. *Nat. Genet.* **33**, 85 (2003). [doi:10.1038/ng1066](#) [Medline](#)
  80. I. Borg *et al.*, Disruption of Netrin G1 by a balanced chromosome translocation in a girl with Rett syndrome. *Eur. J. Hum. Genet.* **13**, 921 (2005). [doi:10.1038/sj.ejhg.5201429](#) [Medline](#)
  81. J. A. Briant *et al.*, Evidence for association of two variants of the nociceptin/orphanin FQ receptor gene OPRL1 with vulnerability to develop opiate addiction in Caucasians. *Psychiatr. Genet.* **20**, 65 (2010). [doi:10.1097/YPG.0b013e32833511f6](#) [Medline](#)
  82. S. R. Williams *et al.*, Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems. *Am. J. Hum. Genet.* **87**, 219 (2010). [doi:10.1016/j.ajhg.2010.07.011](#) [Medline](#)
  83. B. Borroni *et al.*, Atypical presentation of a novel Presenilin 1 R377W mutation: Sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. *Neurol. Sci.* **33**, 375 (2012). [doi:10.1007/s10072-011-0714-1](#) [Medline](#)
  84. A. Goffin, L. H. Hoefsloot, E. Bosgoed, A. Swillen, J. P. Fryns, PTEN mutation in a family with Cowden syndrome and autism. *Am. J. Med. Genet.* **105**, 521 (2001). [doi:10.1002/ajmg.1477](#) [Medline](#)
  85. G. E. Herman *et al.*, Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly. *Am. J. Med. Genet. A.* **143**, 589 (2007). [doi:10.1002/ajmg.a.31619](#) [Medline](#)
  86. E. M. Arch *et al.*, Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. *Am. J. Med. Genet.* **71**, 489 (1997). [doi:10.1002/\(SICI\)1096-8628\(19970905\)71:4<489::AID-AJMG24>3.0.CO;2-B](#) [Medline](#)
  87. E. Trivier *et al.*, Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. *Nature* **384**, 567 (1996). [doi:10.1038/384567a0](#) [Medline](#)
  88. K. Merienne *et al.*, A missense mutation in RPS6KA3 (RSK2) responsible for non-specific mental retardation. *Nat. Genet.* **22**, 13 (1999). [doi:10.1038/8719](#) [Medline](#)
  89. M. Field *et al.*, Mutations in the RSK2(RPS6KA3) gene cause Coffin-Lowry syndrome and nonsyndromic X-linked mental retardation. *Clin. Genet.* **70**, 509 (2006). [doi:10.1111/j.1399-0004.2006.00723.x](#) [Medline](#)
  90. K. Taniue, T. Oda, T. Hayashi, M. Okuno, T. Akiyama, A member of the ETS family, EHF, and the ATPase RUVBL1 inhibit p53-mediated apoptosis. *EMBO Rep.* **12**, 682 (2011). [doi:10.1038/embor.2011.81](#) [Medline](#)
  91. Y. Feng, N. Lee, E. R. Fearon, TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling. *Cancer Res.* **63**, 8726 (2003). [Medline](#)
  92. A. V. Budanov, M. Karin, p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. *Cell* **134**, 451 (2008). [doi:10.1016/j.cell.2008.06.028](#) [Medline](#)
  93. K. Buysse *et al.*, Delineation of a critical region on chromosome 18 for the del(18)(q12.2q21.1) syndrome. *Am. J. Med. Genet. A.* **146A**, 1330 (2008). [doi:10.1002/ajmg.a.32267](#) [Medline](#)
  94. A. Hoischen *et al.*, De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. *Nat. Genet.* **42**, 483 (2010). [doi:10.1038/ng.581](#) [Medline](#)
  95. P. Xie *et al.*, Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. *Cell. Signal.* **20**, 1671 (2008). [doi:10.1016/j.cellsig.2008.05.012](#) [Medline](#)
  96. H. Yang, T. Sasaki, S. Minoshima, N. Shimizu, Identification of three novel proteins (SGSM1, 2, 3) which modulate small G protein (RAP and RAB)-mediated signaling pathway. *Genomics* **90**, 249 (2007). [doi:10.1016/j.ygeno.2007.03.013](#) [Medline](#)
  97. R. F. Hevner *et al.*, Tbr1 regulates differentiation of the preplate and layer 6. *Neuron* **29**, 353 (2001). [doi:10.1016/S0896-6273\(01\)00211-2](#) [Medline](#)
  98. B. Z. Yang, S. Han, H. R. Kranzler, L. A. Farrer, J. Gelernter, A genomewide linkage scan of cocaine dependence and major depressive episode in two populations. *Neuropsychopharmacology* **36**, 2422 (2011). [doi:10.1038/npp.2011.122](#) [Medline](#)
  99. X. Huang, C. Langelotz, B. K. Hetfeld-Pechoc, W. Schwenk, W. Dubiel, The COP9 signalosome mediates beta-catenin degradation by deneddylation and blocks adenomatous polyposis coli destruction via USP15. *J. Mol. Biol.* **391**, 691 (2009). [doi:10.1016/j.jmb.2009.06.066](#) [Medline](#)
  100. C. Tian *et al.*, KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis. *Nat. Cell Biol.* **11**, 580 (2009). [doi:10.1038/ncb1864](#) [Medline](#)
- Acknowledgments:** We thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010), Benjamin Vernot, Megan Dennis, Tonia Brown, and other members of the Eichler and Shendure labs for helpful discussions. We are grateful to all of the families at the participating Simons Simplex Collection (SSC) sites, as well as the principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, R. Goin-Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren, E. Wijsman). We appreciate obtaining access to phenotypic data on SFARI Base. Approved researchers can obtain the SSC population dataset described in this study ([https://ordering.base.sfari.org/~browse\\_collection/archive/ssc\\_v13/ui/view](https://ordering.base.sfari.org/~browse_collection/archive/ssc_v13/ui/view)) by applying at <https://base.sfari.org>. This work was supported by grants from the Simons Foundation (SFARI 137578, 191889 to E.E.E., J.S., and R.B.), NIH HD065285 (E.E.E. and J.S.), NIH NS069605 (H.C.M.), and R01 NS064077 (D.D.). E.B. is an Alfred P. Sloan Research Fellow. E.E.E. is an Investigator of the Howard Hughes Medical Institute.

Scientific advisory boards or consulting affiliations: Ariosa Diagnostics (J.S.), Stratos Genomics (J.S.), Good Start Genetics (J.S.), Adaptive Biotechnologies (J.S.), Pacific Biosciences (E.E.E.), SynapDx (E.E.E.), DNAnexus (E.E.E.), and SFARI GENE (H.C.M.). B.J.O. is an inventor on patent PCT/US2009/30620: Mutations in contactin associated protein 2 are associated with increased risk for idiopathic autism. Raw sequencing data available at the National Database for Autism Research, NDARCOL1878.

**Supplementary Materials**

[www.sciencemag.org/cgi/content/full/science.1227764/DC1](http://www.sciencemag.org/cgi/content/full/science.1227764/DC1)

Materials and Methods

Supplementary Text

Figs. S1 to S14

Tables S1 to S18

References (24–100)


23 July 2012; accepted 01 November 2012

Published online 15 November 2012; 10.1126/science.1227764


**Table 1.** Six genes with recurrent de novo mutations. Abbreviations: M-male, F-female, Mut-mutation type, fs-frameshifting indel, ns-nonsense, sp-splice-site, aa-single amino acid deletion, ms-missense, HGVS-Human Genome Variation Society nomenclature; NVIQ-nonverbal intellectual quotient.

Proband	Sex	Gene	Mut	Assay <sup>‡</sup>	HGVS	NVIQ
12714.p1	M	CHD8*	ns	MIP	p.Ser62X	78
13986.p1	M	CHD8*	fs	MIP	p.Tyr747X	38
11654.p1	F	CHD8*	sp	MIP <sup>  </sup> (4)	c.3519-2A>G	41
13844.p1	M	CHD8*	ns	EX	p.Gln1238X	34
14016.p1	M	CHD8*	ns	MIP	p.Arg1337X	92
12991.p1	M	CHD8*	fs	MIP	p.Glu2103ArgfsX3	67
12752.p1	F	CHD8*	fs	EX	p.Leu2120ProfsX13	93
14233.p1	M	CHD8*	fs	MIP	p.Asn2371LysfsX2	19
14406.p1	M	CHD8*	aa	MIP	p.His2498del	98
12099.p1	M	DYRK1A*	fs	MIP <sup>  </sup> (4)	p.Ile48LysfsX2	55
13890.p1	F	DYRK1A*	sp	EX	c.1098+1G>A	42
13552.p1	M	DYRK1A*	fs	MIP <sup>¶</sup> (6)	p.Ala498ProfsX94	66
11691.p1	M	GRIN2B <sup>†</sup>	fs	MIP <sup>§,  </sup> (3)	p.Ser34GlnfsX25	62
13932.p1	M	GRIN2B <sup>†</sup>	ms	MIP	p.Cys456Tyr	55
12547.p1	M	GRIN2B <sup>†</sup>	ns	MIP <sup>§</sup>	p.Trp559X	65
12681.p1	F	GRIN2B <sup>†</sup>	sp	EX	c.2172-2A>G	65
14433.p1	M	PTEN	ms	MIP	p.Thr131Ile	50
14611.p1	M	PTEN	fs	MIP	p.Cys136MetfsX44	33
11390.p1	F	PTEN	ms	EX	p.Thr167Asn	77
12335.p1	F	TBL1XR1*	ms	EX	p.Leu282Pro	47
14612.p1	M	TBL1XR1*	fs	MIP	p.Ile397SerfsX19	41
11480.p1	M	TBR1 <sup>†</sup>	fs	EX	p.Ala136ProfsX80	41
13814.p1	M	TBR1 <sup>†</sup>	ms	MIP	p.Lys228Glu	78
13796.p1	F	TBR1 <sup>†</sup>	fs	MIP <sup>  </sup> (4)	p.Ser351X	63

\*Part of 49-member connected component reported in (3). †Part of expanded 74-member connected component. ‡Primary assay that identified the variant. ††Proband was exome sequenced by cited study and variant was ††not reported or ††reported. §Variant reported in MIP screen from (3).



**Fig. 1.** Massively multiplex targeted sequencing identifies recurrently mutated genes in ASD probands. **(A)** Schematic showing design and general workflow of a modified MIP method enabling ultra-low-cost candidate gene resequencing in very large cohorts (figs. S1-S7 and tables S1-S9) (10). **(B to E)** Protein diagrams of four genes with multiple de novo mutation events. Significant protein domains for the largest protein isoform are shown (colored regions) as defined by SMART (23) with mutation locations indicated. **(B)** CHD8. **(C)** GRIN2B. **(D)** TBR1. **(E)** DYRK1A. Bold variants are nonsense, frameshifting indels or at splice-sites (intron-exon junction is indicated). Domain abbreviations: CHR-chromatin organization modifier, DEX-DEAD-like helicases superfamily, HELC-helicase superfamily C-terminal, BRK-domain in transcription and CHROMO domain helicases, GLU-ligated ion channel L-glutamate- and glycine-binding site, PBP-eukaryotic homologs of bacterial periplasmic substrate binding proteins, TM-transmembrane, STK-serine-threonine kinase catalytic, TBOX-T-box DNA binding.



**Fig. 2.** Locus-specific mutation probabilities and associated phenotypes. **(A)** Estimated p-values for the observed number of additional de novo mutations identified in the MIP screen of 44 ASD candidate genes. Probabilities shown are for observing X or more events of which at least Y belong to the severe class. The observed numbers of mutations in all 44 genes (“Total”) and CHD8 were not seen in any of  $5 \times 10^8$  simulations. Based on the simulation mean (0.0153), the Poisson probability for seven or more severe class CHD8 mutations is  $3.8 \times 10^{-17}$ . Dashed line Bonferroni corrected significance threshold for  $\alpha = 0.05$ . \*Gene product in the 74-member PPI connected component. **(B-D)** Standardized head circumference (HC) Z-scores for SSC. **(B)** All probands screened with superimposed normal distribution (dashed). HC Z-scores for individuals with de novo truncating/splice mutations highlighted for CHD8 (red arrows), DYRK1A (blue arrows), and PTEN (black arrows). **(C and D)** Box and whisker plots of the HC Z-scores for the SSC. Mutations carriers are shown and linked to their respective family members. **(C)** All family members. **(D)** Only proband sex-matched family members.